Wolfgang Wick

Wolfgang Wick is an expert in Neurology at University Hospital Heidelberg (Germany). As of October 2026, ScienceLeadR ranks Wolfgang Wick in the top 1% of experts worldwide for Glioma, Brain Neoplasms and Nervous System Neoplasms. Wolfgang Wick has authored 1,174 publications, the most recent in 2026, and is an investigator in 33 clinical trials, 4 of them ongoing. SLR score: 4,795 (community average: 125). How the SLR is computed.

Neurology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 20, 2026

Organizations

Career arc: 1998 - 2026

Source: PubMed

University Hospital Heidelberg

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1174

Citations

Citations: 85 437 1st author: 97 Last author: 147 Unique author: 17

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Biomarker-guided treatment strategies for patients with gliomas in clinical practice. PMID 42895284 — brain neoplasms, glioma, neoplasms, biomarkers, histones, glioblastoma, peptide hydrolases, therapeutics	Neuro Oncol	2026	0
Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization. PMID 42789103 — epigenomics, neoplasms, pathology, classification, complement system proteins, tissues, neurology	Acta Neuropathol	2026	0
Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY). PMID 42607618 — astrocytoma, neoplasms, glioblastoma	Eur J Cancer	2026	0
Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy. PMID 42640729 — radiotherapy, glioblastoma	J Clin Invest	2026	0
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial. PMID 42547583 — vaccines, astrocytoma, neoplasms	Nat Cancer	2026	2

Clinical Studies 33

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Study Chair: 3 Study Director: 2

By phase:

Phase 3 13

N/A 9

Phase 1 6

Phase 2 3

Phase 1/Phase 2 2

By status:

Completed 22

Active not recruiting 5

Recruiting 4

Terminated 2

By type:

Interventional 31

Observational 2

By Monocentric/Multicentric:

monocentric 9

multicentric2to4 2

multicentric5to9 3

multicentricup10 19

Main Topics

Nervous System Diseases 11

Cardiovascular Diseases 4

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Vorasidenib in CNS WHO Grade 2 IDH mutant Diffuse Glioma NCT07240662 — glioma, therapeutics	N/A	Recruiting	2025
Lumbar Drainage of Intraventricular Hemorrhage NCT06510842 — drainage, hemorrhage, fibrinolysis, hydrocephalus, weaning	N/A	Recruiting	2025
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas) NCT05331521 — radiotherapy, brain neoplasms, quality of life, glioma, bone marrow, temozolomide, brain, neoplasms, lomustine, recycling, drug therapy, chemoradiotherapy, vincristine, diagnosis, procarbazine, therapeutics, oligodendroglioma, chemotherapy	Phase 3	Recruiting	2021
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3 Mutated Gliomas NCT04808245 — radiotherapy, injections, skin, cells, imiquimod, glioma, vaccines, immunotherapy, vaccination, histones, glioblastoma, therapeutics, protein subunit vaccines	Phase 1	Active not recruiting	2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice